作者
Donald A Berry, Shouhao Zhou, Howard Higley, Lata Mukundan, Shuangshuang Fu, Gregory H Reaman, Brent L Wood, Gary J Kelloff, J Milburn Jessup, Jerald P Radich
发表日期
2017/7/1
期刊
JAMA oncology
卷号
3
期号
7
页码范围
e170580-e170580
出版商
American Medical Association
简介
Importance
Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with acute lymphoblastic leukemia (ALL) with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development.
Objective
To quantify the relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediatric and adult ALL using publications of clinical trials and other databases.
Data Sources
Clinical studies in ALL identified via searches of PubMed, MEDLINE, and clinicaltrials.gov.
Study Selection
Our search and study screening process adhered to the PRISMA Guidelines. Studies that addressed EFS or OS by MRD status in patients with ALL were included; reviews, abstracts, and studies with fewer than 30 patients …
学术搜索中的文章
DA Berry, S Zhou, H Higley, L Mukundan, S Fu… - JAMA oncology, 2017